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Objectives:Molecular diagnosis of cystic ﬁbrosis (CF) is essential for the provision
of genetic counselling, prenatal diagnosis, cascade screening in families, as well
as for understanding the genotype-phenotype relationship. The large number of
different mutations in CFTR gene makes the genetic diagnosis of CF difﬁcult. From
the start of molecular diagnostics CF, many different techniques (ARMS, reverse
hybridisation, SSCP, DGGE, HRM, MLPA, direct sequencing) have been applied
to detect CF mutation. Next-generation sequencing (NGS) technology enables us
to improve efﬁciency of current methods.
Methods: We evaluated in our laboratory the multiplex PCR strategy (CFTR
MASTER, Multiplicon) to generate the patient’s library followed by pyrosequencing
using a NGS platform (454 GS Junior, Roche) and subsequent bioinformatics
analysis based on the software Sequence Pilot (JSI Medical Systems). All sequence
changes were conﬁrmed by Sanger sequencing.
Results: We have assessed the suitability of this workﬂow to be applied in
CF molecular diagnostics using a cohort 24 CF patients displaying a severe
respiratory and digestive phenotype. The NGS sequencing data provided an
adequate depth of sequencing coverage to accurately detect the CFTR exome.
Common and rare CF mutations and coding SNPs were detected. Three novel
sequence changes we identiﬁed, two missense c.729G>A, c. 2834C>T, and
c.2537–2547delinsTCGGTCACAAGAG mutations. This sequence changes have
been tested by conservation study to elucidate their signiﬁcance as a CF causative
mutations.
Conclusion: NGS is changing genetic diagnosis CF due to its huge sequencing
capacity, cost-effectiveness, precise and quick results.
WS11.2 Age related cut-off levels for immunoreactive trypsin (IRT) in
healthy newborns in the ﬁrst two months of life
T. Torresani1, C.S. Rueegg2,3, M. Baumgartner1, R. Fingerhut1, J. Barben4, and
the Swiss Cystic Fibrosis Screening Group. 1Swiss Newborn Screening Laboratory,
University Children’s Hospital of Zu¨rich, Zurich, Switzerland; 2Institute of Social
and Preventive Medicine, University of Bern, Bern, Switzerland; 3Department of
Health Sciences and Health Policy, University of Lucerne, Luzern, Switzerland;
4Division of Pediatric Pulmonology, Children’s Hospital of St. Gallen, St. Gallen,
Switzerland
Background: Newborn screening (NBS) for CF, based on an IRT-DNA-IRT proto-
col, was introduced in Switzerland in 2011. In the DNA panel used in our NBS, only
the seven most common Swiss CFTR mutations were analyzed. If IRT was above
the cut-off (>50 ng/ml) and no mutation was detected, a second IRT ﬁlterpaper
specimen was requested. So far there are no data on IRT levels in newborn babies
aged several weeks. We aimed therefore at calculating the percentiles for IRT in
the ﬁrst two months of life in relation to the age at sampling.
Methods: The second IRT specimens were usually collected by the family physician
in the 3rd to 5th week of life and mailed to the NBS laboratory. IRT was measured
with the Neonatal IRT Kit on the GSP Instrument both from PerkinElmer (Turku,
Finland). Analysis was done on the day the specimens arrived in the laboratory.
Babies with an IRT >50 ng/ml were considered screening positive and referred to
the CF center for sweat test (ST). The screening negative results were divided in
four groups according to the age at sampling: 15−21 d, 22−28 d, 29−35 d and >36 d.
Results: By December 2012, 511 IRT results were collected and assigned to one
of the four groups as follows: 214, 180, 85, and 32. Mean IRT values of the groups
were 25.6, 22.2, 19.9 and 17.9 ng/ml, respectively. The 99.9 Percentile for each
group was 49.8, 49.0, 37.2, and 29.6 ng/ml.
Conclusions: Our results document the signiﬁcant decrease of IRT levels in healthy
babies during the ﬁrst two months of life. When performing NBS for CF using
repeated IRT measurements, the decline of IRT in relation to the age at time of
sampling has to be taken into account when interpreting the results.
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Background: Newborn screening (NBS) for CF, based on an IRT-DNA-IRT protocol,
was introduced in Switzerland in 2011. The goal of our program is to detect all children
with CF but not equivocal CF (ECF). It was closely monitored and evaluated after 12,
24, and 36 months. Based on the evaluation, we adapted the program after 1 and
2 years. The aim of this study was to investigate the ratio of CF to ECF diagnoses in
the 3 time periods.
Methods: All children with a positive screening result were referred to a CF center for
a sweat test (ST). In the ﬁrst year (2011), an extended DNA analysis was performed
when the ST was positive or borderline. This led to long delays when STs had to
be repeated. In 2012, we performed extended DNA analysis immediately when STs
were inconclusive or impossible, to reduce the waiting time for a ﬁnal diagnosis. A
consecutive increased number of ECF in 2012 led to a further change in algorithm:
When the ST was not possible, we determined fecal elastase (FE) before extensive
DNA analysis. When FE was negative we repeated the ST when the child’s weight was
>4000 g (year 2013).
Results: By December 2013, 256 children had been screened positive and referred to a
CF center for investigations. In 73 CF was conﬁrmed, 10 had an ECF and 160 children
were negative (1 child moved abroad, 1 died, 11 not yet fully investigated). In 2011,
the ratio CF/ECF was 8:1 (27/3), in 2012, 4:1 (26/6), and in 2013 20:1 (20/1).
Conclusion: In addition to the screening process in the laboratory, the algorithm used in
the CF centers can strongly affect the ratio of CF versus ECF. With a close monitoring
and simple adaptions, the number of ECF can be reduced.
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Objectives: Diagnosis of CF allows relatives of the patient to know their status
regarding the mutation that segregate in their family. This test (called family or
cascade carrier testing) enables detection of new 1-in-4 risk couples and thus
prevention in families. Our study aimed to report the uptake of carrier testing
in an area where CF is frequent (Finiste`re, western Brittany, France).
Methods: All patients born in our district between 1980 and 2004 were eligible
for the present study. Here we presented data from the ﬁrst 12 families included.
Family trees were faced with the carrier tests made in those families in the sole
genetic laboratory of our area.
Results: To date, 320 family members have been identiﬁed, and 145 were eligible
for testing (adult, living in our district, alive at time of diagnosis). Of them 72
performed the test, leading to a percentage of uptake of 49.7% (95%CI: [41.5%;
57.8%]). Testing identiﬁed 39 carriers (54.2%). Among them 37 were in couples
and 27 had their spouse screened. Finally, we identiﬁed 2 1-in-4 risk couples (1
sister and 1 uncle/aunt couples), who requested prenatal diagnosis 6 times. Four
affected pregnancies were detected and terminated. Moreover, family testing enables
25 heterozygote couples and 101 negative relatives (by testing or by deduction) to
be ascertained (total information rate 43.8%).
Conclusion:We assess, for the ﬁrst time in Europe, uptake of family testing and its
public health implications. These preliminary results tend to reveal a higher uptake
in our area than previously reported in Australia (Victoria State: 11.8%).
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